ProBioGen, Immunogenesis in cell line development agreement

By Vassia Barba

- Last updated on GMT

(Image: Getty/fizkes)
(Image: Getty/fizkes)

Related tags CDMO Contract manufacturing organisation

Immunogenesis is tapping into ProBioGen’s manufacturing capabilities for its immuno-oncology lead candidate, as the potential treatment enters the clinic.

Berlin, Germany-based ProBioGen is a contract development and manufacturing organization (CDMO) focusing on production of therapeutic antibodies and glycoproteins.

The service provider announced that it has signed an agreement with Immunogenesis, under which it will manufacture the latter company’s monoclonal antibody lead candidate, a potential treatment with an immuno-oncology indication.

A spin-off of University of Texas, Immunogenesis will utilize ProBioGen’s Chinese hamster ovary (CHO)-based expression platform, known as CHO.RIGHT, that enables high-titer cell line development.

The partnership will see ProBioGen conduct cell line development, process development and good manufacturing practice (GMP) manufacturing work in 1,000L bioreactor scale, in order to cover the clinical supply needs for Immunogenesis’ project.

Immunogenesis holds a pipeline focusing on achieving effective immunity against non-inflamed tumors, known as ‘cold’ tumors.

This means that the developer looks to generate sufficient anti-tumor T cells; subsequently protect and expand these cells inside the tumor; and ultimately achieve reduction in hostile tumor metabolism.

Commenting on the partnership with ProBioGen, Michael Curran, founder of Immunogenesis, stated that the CDMO forms the right partner as it holds the required scientific expertise and the ‘can-do’ mindset to assist in the realization of Immunogenesis’ scientific project.

Financial terms of the partnership were not disclosed.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more